Roche Receives FDA Approval For The First Companion Diagnostic To Identify Patients With HER2-Ultralow Metastatic Breast Cancer Eligible For ENHERTU
As seen in the DESTINY-Breast06 trial, a pproximately 20-25 percent of hormone receptor (HR)-positive, HER2- ...
Hosted on MSN2m
Hiroyuki Okuzawa succeeds Sunao Manabe as Daiichi Sankyo CEO
Before this development, Daiichi Sankyo and AstraZeneca’s ADC Enhertu (trastuzumab deruxtecan) received approval from the US ...